Shanghai Fosun Pharmaceutical (02196.HK)Board of directors andFosun (00656.HK)The board of directors announced that on October 26, 2021: Shanghai Fosun Pharmaceutical Industry and the selling shareholders entered into equity transfer agreements respectively. Shanghai Fosun Pharmaceutical Industry agreed to purchase a total of about 32.52% of its respective target company (Chengdu Antejin Biotechnology Co., Ltd.) from the selling shareholders for a total cash consideration of about 1108.0338 million yuan. And Shanghai Fosun Pharmaceutical Industries entered into a capital increase agreement with the target company and existing shareholders. Shanghai Fosun Pharmaceutical Industries intends to subscribe for 47958605 yuan of new registered capital of the target company at a price of 2,898 million yuan, accounting for 60% of the total enlarged equity of the target company after the completion of the capital increase.